JPWO2021087016A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021087016A5 JPWO2021087016A5 JP2022525094A JP2022525094A JPWO2021087016A5 JP WO2021087016 A5 JPWO2021087016 A5 JP WO2021087016A5 JP 2022525094 A JP2022525094 A JP 2022525094A JP 2022525094 A JP2022525094 A JP 2022525094A JP WO2021087016 A5 JPWO2021087016 A5 JP WO2021087016A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- heavy chain
- light chain
- pharmaceutical composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025131369A JP2025170788A (ja) | 2019-11-01 | 2025-08-06 | 癌の治療のための抗ｃｄ２７抗体の投薬計画 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962929538P | 2019-11-01 | 2019-11-01 | |
| US62/929,538 | 2019-11-01 | ||
| PCT/US2020/057817 WO2021087016A1 (en) | 2019-11-01 | 2020-10-29 | Dosing regimen of anti-cd27 antibodies for treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025131369A Division JP2025170788A (ja) | 2019-11-01 | 2025-08-06 | 癌の治療のための抗ｃｄ２７抗体の投薬計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500480A JP2023500480A (ja) | 2023-01-06 |
| JP2023500480A5 JP2023500480A5 (https=) | 2023-11-08 |
| JPWO2021087016A5 true JPWO2021087016A5 (https=) | 2023-11-08 |
Family
ID=75716307
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525094A Pending JP2023500480A (ja) | 2019-11-01 | 2020-10-29 | 癌の治療のための抗ｃｄ２７抗体の投薬計画 |
| JP2025131369A Pending JP2025170788A (ja) | 2019-11-01 | 2025-08-06 | 癌の治療のための抗ｃｄ２７抗体の投薬計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025131369A Pending JP2025170788A (ja) | 2019-11-01 | 2025-08-06 | 癌の治療のための抗ｃｄ２７抗体の投薬計画 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230192876A1 (https=) |
| EP (1) | EP4051712A4 (https=) |
| JP (2) | JP2023500480A (https=) |
| KR (1) | KR20220092569A (https=) |
| CN (1) | CN114761432A (https=) |
| AU (1) | AU2020372912A1 (https=) |
| BR (1) | BR112022008233A2 (https=) |
| CA (1) | CA3159366A1 (https=) |
| MX (1) | MX2022005245A (https=) |
| WO (1) | WO2021087016A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| WO2025188553A1 (en) * | 2024-03-05 | 2025-09-12 | Merck Sharp & Dohme Llc | Methods and compositions for treatment of cancer with anti-cd27 antibodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011275749C1 (en) * | 2010-07-09 | 2015-09-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to CD27 |
| US10392442B2 (en) * | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| JOP20190055A1 (ar) * | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
-
2020
- 2020-10-29 WO PCT/US2020/057817 patent/WO2021087016A1/en not_active Ceased
- 2020-10-29 EP EP20881154.7A patent/EP4051712A4/en active Pending
- 2020-10-29 JP JP2022525094A patent/JP2023500480A/ja active Pending
- 2020-10-29 CN CN202080084116.1A patent/CN114761432A/zh active Pending
- 2020-10-29 BR BR112022008233A patent/BR112022008233A2/pt unknown
- 2020-10-29 AU AU2020372912A patent/AU2020372912A1/en active Pending
- 2020-10-29 CA CA3159366A patent/CA3159366A1/en active Pending
- 2020-10-29 KR KR1020227018204A patent/KR20220092569A/ko active Pending
- 2020-10-29 MX MX2022005245A patent/MX2022005245A/es unknown
- 2020-10-29 US US17/772,229 patent/US20230192876A1/en not_active Abandoned
-
2025
- 2025-08-06 JP JP2025131369A patent/JP2025170788A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507932A5 (https=) | ||
| JP2020508317A5 (https=) | ||
| CN111065411A (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2021528423A5 (https=) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2014533279A5 (https=) | ||
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| JP2015532292A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| JP2021528438A5 (https=) | ||
| EP4288100A1 (en) | Methods for local and systemic treatment of cancers, tumors and tumor cells | |
| JP2019524820A5 (https=) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2021518348A5 (https=) | ||
| RU2020133811A (ru) | Фармацевтические комбинации | |
| JPWO2020096915A5 (https=) | ||
| JP2020521798A5 (https=) | ||
| JPWO2021087016A5 (https=) | ||
| CN116113411A (zh) | 用于治疗软组织肉瘤的联用药物 | |
| CN112955148A (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| JP2020507569A5 (https=) | ||
| JPWO2023041622A5 (https=) | ||
| CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 | |
| JPWO2021178657A5 (https=) |